Compare ELTX & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTX | PROF |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.9M | 238.1M |
| IPO Year | 2014 | 2017 |
| Metric | ELTX | PROF |
|---|---|---|
| Price | $12.50 | $7.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $18.00 | $12.00 |
| AVG Volume (30 Days) | 110.2K | ★ 196.0K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.29 | 25.89 |
| EPS | N/A | ★ 1.41 |
| Revenue | $2,301,000.00 | ★ $16,098,000.00 |
| Revenue This Year | N/A | $92.40 |
| Revenue Next Year | N/A | $64.10 |
| P/E Ratio | ★ N/A | $4.72 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $4.70 | $3.92 |
| 52 Week High | $14.93 | $8.95 |
| Indicator | ELTX | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 59.69 | 63.48 |
| Support Level | $9.85 | $7.00 |
| Resistance Level | $12.52 | $7.97 |
| Average True Range (ATR) | 0.95 | 0.42 |
| MACD | 0.26 | 0.11 |
| Stochastic Oscillator | 64.98 | 100.00 |
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.